Case Report

Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies

Cheng Cheng, Jose Kuzhively, and Sanford Baim

Division of Endocrinology and Metabolism, Rush University Medical Center, Chicago, IL, USA

Correspondence should be addressed to Sanford Baim; sanford.baim@rush.edu

Received 15 October 2016; Accepted 19 December 2016; Published 12 January 2017

Academic Editor: Lucy Mastrandrea

Copyright © 2017 Cheng Cheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Here we describe, to our knowledge, the first case where an evolution of mechanisms responsible for hypercalcemia occurred in undifferentiated thymic carcinoma and discuss specific management strategies for hypercalcemia of malignancy (HCM). *Case Description.* We report a 26-year-old male with newly diagnosed undifferentiated thymic carcinoma associated with HCM. Osteolytic metastasis-related hypercalcemia was presumed to be the etiology of hypercalcemia that responded to intravenous hydration and bisphosphonate therapy. Subsequently, refractory hypercalcemia persisted despite the administration of bisphosphonates and denosumab indicative of refractory hypercalcemia. Elevated 1,25-dihydroxyvitamin D was noted from the second admission with hypercalcemia responding to glucocorticoid administration. A subsequent PTHrP was also elevated, further supporting multiple mechanistic evolution of HCM. The different mechanisms of HCM are summarized with the role of tailoring therapies based on the particular mechanism underlying hypercalcemia discussed. *Conclusion.* Our case illustrates the importance of a comprehensive initial evaluation and reevaluation of all identifiable mechanisms of HCM, especially in the setting of recurrent and refractory hypercalcemia. Knowledge of the known and possible evolution of the underlying mechanisms for HCM is important for application of specific therapies that target those mechanisms. Specific targeting therapies to the underlying mechanisms for HCM could positively affect patient outcomes.

1. Clinical Presentation

A 26-year-old African American male, with no significant past medical history, presented to the emergency department in early November 2016 with complaints of fever, malaise, 18 lb weight loss over 2 weeks, and multiple neck masses. Medications prior to admission consisted of cyclobenzaprine, meloxicam, tramadol, and recreational use of marijuana. Initial imaging revealed an anterior mediastinal mass with intrathoracic lymphadenopathy, bilateral pulmonary nodules, and spine lesions on CT.

Physical exam demonstrated bilateral supraclavicular lymphadenopathy that was tender to palpation, pain on palpation of the cervical and lumbar spine, and normal neurological exam.

Labs on admission were notable for corrected total calcium (Calc) of 15.1 mg/dL, ionized calcium (iCa) of 1.59 mg/dL (ref: 0.95–1.32 mg/dL), PTH of 4.8 pg/mL (ref: 8–85 pg/mL), phosphorus (Phos) of 2 mg/dL (ref: 2/5–4.6 mg/dL), creatinine of 1.16 mg/dL (ref: 0.75–1.2 mg/dL), and blood count

with no atypical cells seen on the differential. Aggressive IV hydration with normal saline at a rate of 250 cc/hr was promptly started and maintained throughout this admission with administration of pamidronate 90 mg on hospital day 2. Additional studies included supraclavicular lymph node and bone marrow biopsies consistent with Epstein-Barr virus positive metastatic undifferentiated, non-keratinizing, lymphoepithelioma-like carcinoma of thymic origin. After undergoing staging with additional imaging, the patient completed his first cycle of chemotherapy with cisplatin, doxorubicin, and cytoxan in the next 2 weeks. His Calc decreased to 10.5 mg/dL at the time of discharge.

Approximately 2 weeks after discharge, the patient was readmitted for a second admission with increasing somnolence. Laboratory analysis disclosed Calc of 15.4 mg/dL and iCa of 1.72 mg/dL for which IV hydration with normal saline at 250 cc/hr was initiated followed by pamidronate 90 mg and calcitonin 300 U with improvement of iCa to as low as 1.16 mg/dL. PTH-related peptide (PTHrP) and 1,25-dihydroxyvitamin D (calcitriol) were sent during this

FIGURE 1: Evolution of hypercalcemia in relation to medical therapies instituted. Please note that majority of ionized calcium data from first admission are unavailable. Also, ionized calcium levels are unavailable on 1/5/2016 when denosumab was administered.

admission but results were not available. Repeat MRI of the entire spine noted new hyperintense metastatic lesions. Over the ensuing 3 days, iCa slowly increased to 1.46 mg/dL and required administration of zoledronate 4 mg resulting in normalization of iCa between 1 and 1.1 mg/dL for the rest of the admission (Figure 1). The patient subsequently began cycle 2 of cisplatin, doxorubicin, and cytoxan which was completed prior to discharge with a plan to initiate denosumab as an outpatient.

During outpatient follow-up and 5 days after discharge, a rapid rebound in hypercalcemia occurred with Calc of 12.6 mg/dL and iCa of 1.46 mg/dL, requiring administration of denosumab 120 mg which decreased iCa to 1.25 mg/dL (Figure 1). A second dose of denosumab 120 mg was given 1 week later with concurrent Calc of 12.7 mg/dL.

One month later, the patient was readmitted with altered mental status with Calc of 13.6 mg/dL, iCa of 1.53 mg/dL, Phos of 1.6 mg/dL, and normal renal function. The patient received prompt administration of IV hydration with normal saline and pamidronate 90 mg. Although iCa level decreased to 1.3–1.4 mg/dL within 2 days, it rebounded over the next 24–48 hours to 1.64 mg/dL, requiring further administration of zoledronate 4 mg (Figure 1).

At this time, it was noted that his 1,25-dihydroxyvitamin D level from the previous admission was elevated at 131 pg/mL (ref: 18–64 pg/mL) and PTHrP at 27 pg/mL (ref: 14–27 pg/mL). Methylprednisolone 60 mg per day was subsequently instituted over the next 2 days with decrease in iCa level to 1.3–1.4 mg/dL (Figure 1).

However, the patient continued to clinically deteriorate, despite iCa being maintained at 1.3–1.4 mg/dL (Figure 1) with development of multiorgan failure, and he expired shortly after. It is noteworthy that the third admission repeated PTHrP and calcitriol levels that returned to the medical record posthumously were 58 pg/mL and 499 pg/mL, respectively.

2. Introduction

Hypercalcemia of malignancy (HCM) commonly presents as the initial manifestation of undiagnosed cancer. HCM is a paraneoplastic syndrome with poor prognosis and up to 50% mortality within the first 2 months of the diagnosis [1, 2]. HCM may be caused by either humoral factors (humoral hypercalcemia of malignancy, HHM) which indirectly enhances bone resorption or direct skeletal invasion by malignant cells (osteolytic metastasis-related hypercalcemia, OMRH). Humoral factors responsible for hypercalcemia are usually PTHrP in 80% of HCM [3] followed by excessive 1,25-dihydroxyvitamin D production by tumor cells or macrophages (calcitriol-induced hypercalcemia, HHM-CIH) in less than 1% [3] and excessive ectopic parathyroid hormone (PTH) producing tumors being rare. Another rare humoral cause is the production of excessive systemic cytokine and/or chemokine induced bone resorption (HHM-SCCBBR) with normal PTHrP, calcitriol, and PTH levels and no evidence of OMRH [4]. Usually HCM has a single etiology. Rarely interplay of multiple mechanisms can be the cause [5–8].

The currently elucidated five known mechanisms for HCM and their respective associated cancers are summarized in Table 1. Here we present a case of severe hypercalcemia due to undifferentiated thymic carcinoma involving several hypercalcemia inducing mechanisms that evolved over the course of three admissions. The response of serum calcium to the institution of different therapies based on the identification of the underlying mechanisms is additionally described.

3. Discussion

Bisphosphonates, namely, pamidronate and zoledronate, have essentially become the standard therapy following aggressive fluid resuscitation in the management of HCM. The mechanism of action of bisphosphonates in the treatment

TABLE 1: Respective cancers associated with mechanisms of hypercalcemia of malignancy [4, 9–30].

	Hematologic malignancy	Solid organ malignancy
Calcitriol-induced hypercalcemia	(i) Non-Hodgkin's lymphoma (ii) Hodgkin's lymphoma (iii) Chronic lymphocytic leukemia	(i) Gastrointestinal stromal tumor (ii) Glioblastoma multiforme (iii) Metastatic squamous cell carcinoma of tongue (iv) Non-small cell lung carcinoma (v) Metastatic carcinoma of unknown primary (vi) Ovarian dysgerminoma (vii) Renal cell carcinoma (viii) Seminoma
PTHrP-related hypercalcemia	(i) Non-Hodgkin's lymphoma (ii) Chronic myelogenous leukemia (iii) Chronic lymphocytic leukemia (iv) Hodgkin's lymphoma (v) Multiple myeloma (vi) Plasma cell leukemia (vii) Waldenstrom's macroglobulinemia	(i) Squamous cell carcinoma ^a (ii) Adenocarcinoma ^b (iii) Benign congenital mesoblastic nephroma (iv) Bladder cancer (v) Epithelioid hemangioendothelioma (vi) Melanoma (vii) Merkel cell carcinoma (viii) Myxoid sarcoma (ix) Neuroendocrine tumor (x) Seminoma (xi) Uterine leiomyoma
Local osteolysis	(i) Acute lymphocytic leukemia (ii) Multiple myeloma (iii) Non-Hodgkin's lymphoma	(i) Breast cancer (ii) Lung cancer
Ectopic PTH secretion	(i) Acute myelogenous leukemia	(i) Gastric carcinoma (ii) Lung cancer (a) Small cell (b) Squamous cell (iii) Neuroendocrine cancer of pancreas (iv) Thyroid cancer (a) Medullary (b) Papillary adenocarcinoma (v) Ovarian carcinoma (vi) Thymoma (vii) Rhabdomyosarcoma
Cytokine-induced hypercalcemia	(i) Acute lymphocytic leukemia (ii) Multiple myeloma (iii) Non-Hodgkin's lymphoma (a) Diffuse large B-cell lymphoma (b) Follicular lymphoma (c) Adult T-cell leukemia/lymphoma	(i) Squamous cell carcinoma of hand

^a Anus, esophagus, head and neck cancer, lung, manubrium, parotid, penis, skin, scrotum, and vulva [9].^b Breast, cholangiocarcinoma, colon, duodenum, endometrium, lung, ovary, pancreas, renal cell, and stomach [9].

of HCM is the inhibition of osteoclast-mediated bone resorption, increased osteoclast apoptosis, and decreased osteoblast apoptosis [25, 31]. The rapid rebound of hypercalcemia despite the additional administration of bisphosphonate therapy in our patient, even after his second admission (Figure 1), is consistent with incomplete inhibition of bone resorption [32]. This is often observed with progression of tumor by means of the specific underlying mechanism for HCM whether it be OMRH, PTHrP, or HHM-SCCBBR.

The implementation of the novel antiresorptive agent denosumab, a RANKL antibody that inhibits osteoclastic activity, was followed by improvement of iCal to the upper limit of the normal range which persisted until the third admission (Figure 1). This course of action is consistent with findings from recent studies in which the introduction of denosumab is of particular benefit in HCM refractory to bisphosphonates [33]. The recurrent hypercalcemia that prompted our patient's last admission was indicative of both

bisphosphonate and denosumab failure but demonstrated dramatic response to glucocorticoid therapy (Figure 1) which is consistent with a different mechanism of HCM or HHM-CIH.

The elevated 1,25-dihydroxyvitamin D, as noted in our case, did trigger the prompt administration of prednisone therapy which led to rapid improvement in calcium levels (Figure 1). Although HHM-CIH is widely recognized and studied extensively in granulomatous diseases, increased expression and activity of 1- α hydroxylase resulting in overproduction of serum 1,25-dihydroxyvitamin D have also been demonstrated in *in vivo* studies investigating hypercalcemia associated with dysgerminomas [34] and B-cell lymphoma [35]. The treatment of HHM-CIH is glucocorticoid therapy that inhibits 1- α hydroxylase activity, blocking conversion of calcidiol to calcitriol, resulting in decreased absorption of calcium from the intestine, reabsorption of calcium in the renal tubules, and decreased bone resorption [2]. The optimal glucocorticoid treatment dose and duration of therapy remain undefined, with doses ranging from 20 to 400 mg of prednisone or its equivalent administered daily [9, 36].

Hypercalcemia resulting from multiple mechanisms, HHM-CIH and HHM-PTHrP, has been described in rare cases of HTLV-1 positive ATLL [5], neuroendocrine tumors of the pancreas [6], seminoma [7], and ovarian carcinoma [8]. The mechanism elucidated to cause HHM-SCCBR has been described in conjunction with HHM-PTHrP or OMRH, as observed in multiple myeloma and breast cancer [37, 38]. None of these cases illustrated the simultaneous or independent development of multiple mechanisms underlying HCM over time.

Our case is novel in several aspects from other case reports. The first two admissions were presumed to be associated with OMRH, evidenced by extensive bone metastases. The discovery of a progressive elevation of calcitriol over time, refractoriness of treatment with bisphosphonates and denosumab (Figure 1), and significant response to glucocorticoids therapy is consistent with evolution of an alternative mechanism for HCM. The subsequent discovery of a progressive elevation of PTHrP supports an additional mechanism for HCM in this case.

Our case is also unique given the observation of malignancy associated hypercalcemia in undifferentiated thymic carcinoma. To our knowledge, paraneoplastic hypercalcemia has been previously described in only two cases of squamous cell carcinoma of the thymus [10, 11]. The etiology of hypercalcemia, in one of the aforementioned cases, was believed to be secondary to HHM [11].

4. Conclusion

Our patient represents the first reported case of the progressive evolution of HCM mechanisms as demonstrated by the findings of refractory and recurrent hypercalcemia associated with discovery of an additional specific mechanism that subsequently responded to the targeted treatment.

In patients presenting with paraneoplastic hypercalcemia, especially in the setting of recurrent or refractory hypercalcemia, it is prudent to evaluate all potential mechanisms

of HCM by obtaining measurement of PTH, PTHrP, and calcitriol levels.

Competing Interests

The authors declare that they have no competing interests.

Acknowledgments

The authors thank Dr. Brian W Kim and Dr. Ambika Ambler for their invaluable comments on the article. This work was funded by Department of Endocrinology and Metabolism at Rush University Medical Center.

References

- [1] S. H. Ralston, S. J. Gallacher, U. Patel, J. Campbell, and I. T. Boyle, "Cancer-associated hypercalcemia: morbidity and mortality—clinical experience in 126 treated patients," *Annals of Internal Medicine*, vol. 112, no. 7, pp. 499–504, 1990.
- [2] S.-J. Zhang, Y. Hu, J. Cao et al., "Analysis on survival and prognostic factors for cancer patients with malignancy-associated hypercalcemia," *Asian Pacific Journal of Cancer Prevention*, vol. 14, no. 11, pp. 6715–6719, 2013.
- [3] A. F. Stewart, "Clinical practice. Hypercalcemia associated with cancer," *The New England journal of medicine*, vol. 352, no. 4, pp. 373–379, 2005.
- [4] P. Martens, B. Addissie, and R. Kumar, "Follicular lymphoma presenting with hypercalcaemia: an unusual mechanism of hypercalcaemia," *Acta Clinica Belgica*, vol. 70, no. 3, pp. 200–203, 2015.
- [5] S. R. D. Johnston and P. J. Hammond, "Elevated serum parathyroid hormone related protein and 1,25-dihydroxycholecalciferol in hypercalcaemia associated with adult T-cell leukaemia-lymphoma," *Postgraduate Medical Journal*, vol. 68, no. 803, pp. 753–755, 1992.
- [6] G. G. Van den Eynden, A. Neyret, G. Fumey et al., "PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor," *Bone*, vol. 40, no. 4, pp. 1166–1171, 2007.
- [7] R. Rodríguez-Gutiérrez, M. A. Zapata-Rivera, D. L. Quintanilla-Flores et al., "1,25-dihydroxyvitamin D and PTHrP mediated malignant hypercalcemia in a seminoma," *BMC Endocrine Disorders*, vol. 14, article no. 32, 2014.
- [8] K. Hoekman, Y. I. Tjandra, and S. E. Papapoulos, "The role of 1,25-dihydroxyvitamin D in the maintenance of hypercalcemia in a patient with an ovarian carcinoma producing parathyroid hormone-related protein," *Cancer*, vol. 68, no. 3, pp. 642–647, 1991.
- [9] P. J. Donovan, L. Sundac, C. J. Pretorius, M. C. D'Emden, and D. S. A. McLeod, "Calcitriol-mediated hypercalcemia: causes and course in 101 patients," *Journal of Clinical Endocrinology and Metabolism*, vol. 98, no. 10, pp. 4023–4029, 2013.
- [10] J. M. Negron-Soto and P. N. Cascade, "Squamous cell carcinoma of the thymus with paraneoplastic hypercalcemia," *Clinical Imaging*, vol. 19, no. 2, pp. 122–124, 1995.
- [11] K. Suzuki, H. Tanaka, T. Shibusa et al., "Parathyroid-hormone-related-protein-producing thymic carcinoma presenting as a giant extrathoracic mass," *Respiration*, vol. 65, no. 1, pp. 83–85, 1998.

- [12] M. Demura, T. Yoneda, F. Wang et al., "Ectopic production of parathyroid hormone in a patient with sporadic medullary thyroid cancer," *Endocrine Journal*, vol. 57, no. 2, pp. 161–170, 2010.
- [13] I. J. Diel, J. J. Body, A. T. Stopeck et al., "The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease," *European Journal of Cancer*, vol. 51, no. 11, pp. 1467–1475, 2015.
- [14] P. J. Donovan, N. Achong, K. Griffin, J. Galligan, C. J. Pretorius, and D. S. A. McLeod, "PTHrP-mediated hypercalcemia: causes and survival in 138 patients," *Journal of Clinical Endocrinology and Metabolism*, vol. 100, no. 5, pp. 2024–2029, 2015.
- [15] F. Firkin, H. Schneider, and V. Grill, "Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy," *Leukemia and Lymphoma*, vol. 29, no. 5-6, pp. 499–506, 1998.
- [16] H. Fukasawa, A. Kato, Y. Fujigaki, K. Yonemura, R. Furuya, and A. Hishida, "Hypercalcemia in a patient with B-cell acute lymphoblastic leukemia: a role of proinflammatory cytokine," *The American Journal of the Medical Sciences*, vol. 322, no. 2, pp. 109–112, 2001.
- [17] H. Iguchi, C. Miyagi, K. Tomita et al., "Hypercalcemia caused by ectopic production of parathyroid hormone in a patient with papillary adenocarcinoma of the thyroid gland," *Journal of Clinical Endocrinology and Metabolism*, vol. 83, no. 8, pp. 2653–2657, 1998.
- [18] P. Jasti, V. T. Lakhani, A. Woodworth, and K. M. Dahir, "Hypercalcemia secondary to gastrointestinal stromal tumors: parathyroid hormone-related protein independent mechanism?" *Endocrine Practice*, vol. 19, no. 6, pp. e158–e162, 2013.
- [19] G. Kaiafa, V. Perifanis, N. Kakaletsis, K. Chalvatzi, and A. I. Hatzitolios, "Hypercalcemia and multiple osteolytic lesions in an adult patient with relapsed pre-B acute lymphoblastic leukemia: a case report," *Hippokratia*, vol. 19, no. 1, pp. 78–81, 2015.
- [20] H. Mori, K. Aoki, I. Katayama, K. Nishioka, and T. Umeda, "Humoral hypercalcemia of malignancy with elevated plasma PTHrP, TNF α and IL-6 in cutaneous squamous cell carcinoma," *Journal of Dermatology*, vol. 23, no. 7, pp. 460–462, 1996.
- [21] K. Nakajima, M. Tamai, S. Okaniwa et al., "Humoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literature," *Endocrine Journal*, vol. 60, no. 5, pp. 557–562, 2013.
- [22] S. Nakayama-Ichijima, T. Yokote, K. Iwaki et al., "Hypercalcaemia induced by tumour-derived parathyroid hormone-related protein and multiple cytokines in diffuse large B cell lymphoma, not otherwise specified," *Pathology*, vol. 43, no. 7, pp. 742–745, 2011.
- [23] P. K. Nielsen, Å. K. Rasmussen, U. Feldt-Rasmussen, M. Brandt, L. Christensen, and K. Olgaard, "Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro," *Journal of Clinical Endocrinology and Metabolism*, vol. 81, no. 10, pp. 3793–3796, 1996.
- [24] S. R. Nussbaum, R. D. Gaz, and A. Arnold, "Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone," *New England Journal of Medicine*, vol. 323, no. 19, pp. 1324–1328, 1990.
- [25] R. G. G. Russell, Z. Xia, J. E. Dunford et al., "Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy," *Annals of the New York Academy of Sciences*, vol. 1117, pp. 209–257, 2007.
- [26] T. Srivastava, A. Kats, T. J. Martin, S. Pompolo, and U. S. Alon, "Parathyroid-hormone-related protein-mediated hypercalcemia in benign congenital mesoblastic nephroma," *Pediatric Nephrology*, vol. 26, no. 5, pp. 799–803, 2011.
- [27] G. J. Strewler, A. A. Budayr, O. H. Clark, and R. A. Nissenson, "Production of parathyroid hormone by a malignant nonparathyroid tumor in a hypercalcemic patient," *Journal of Clinical Endocrinology and Metabolism*, vol. 76, no. 5, pp. 1373–1375, 1993.
- [28] E. Tarnawa, S. Sullivan, P. Underwood, M. Richardson, and L. Spruill, "Severe hypercalcemia associated with uterine leiomyoma in pregnancy," *Obstetrics and Gynecology*, vol. 117, no. 2, part 2, pp. 473–476, 2011.
- [29] H. Vacher-Coponat, A. Opris, A. Denizot, B. Dussol, and Y. Berland, "Hypercalcaemia induced by excessive parathyroid hormone secretion in a patient with a neuroendocrine tumour," *Nephrology Dialysis Transplantation*, vol. 20, no. 12, pp. 2832–2835, 2005.
- [30] K. Wong, S. Tsuda, R. Mukai, K. Sumida, and R. Arakaki, "Parathyroid hormone expression in a patient with metastatic nasopharyngeal rhabdomyosarcoma and hypercalcemia," *Endocrine*, vol. 27, no. 1, pp. 83–86, 2005.
- [31] X.-L. Xu, W.-L. Gou, A.-Y. Wang et al., "Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?" *Journal of Translational Medicine*, vol. 11, no. 1, article no. 303, 2013.
- [32] M. I. Hu, I. G. Glezerman, S. Leboulleux et al., "Denosumab for treatment of hypercalcemia of malignancy," *The Journal of Clinical Endocrinology & Metabolism*, vol. 99, no. 9, pp. 3144–3152, 2014.
- [33] N. A. Breslau, J. L. McGuire, J. E. Zerwekh, E. P. Frenkel, and C. Y. Pak, "Hypercalcemia associated with increased serum calcitriol levels in three patients with lymphoma," *Annals of Internal Medicine*, vol. 100, no. 1, pp. 1–6, 1984.
- [34] K. N. Evans, H. Taylor, D. Zehnder et al., "Increased expression of 25-hydroxyvitamin D-1 α -hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy," *The American Journal of Pathology*, vol. 165, no. 3, pp. 807–813, 2004.
- [35] M. Hewison, V. Kantorovich, H. R. Liker et al., "Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages," *Journal of Bone and Mineral Research*, vol. 18, no. 3, pp. 579–582, 2003.
- [36] H. Sternlicht and I. G. Glezerman, "Hypercalcemia of malignancy and new treatment options," *Therapeutics and Clinical Risk Management*, vol. 11, pp. 1779–1788, 2015.
- [37] T. A. Guise and G. R. Mundy, "Cancer and bone," *Endocrine Reviews*, vol. 19, no. 1, pp. 18–54, 1998.
- [38] G. A. Clines and T. A. Guise, "Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone," *Endocrine-Related Cancer*, vol. 12, no. 3, pp. 549–583, 2005.